Press Releases

PTC Therapeutics, Inc. is committed to serving the interests of all our stakeholders.
Danya
Living with
Duchenne Muscular Dystrophy,
Ukraine
DANYA - Duchenne Muscular Dysthropy- Ukraine

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.


Date Title and Summary View
Apr 27, 2023 PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
–  First-quarter 2023 total revenue of $220 million , representing 48% year-over-year growth - – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed –   SOUTH PLAINFIELD, N.J. , April 27, 2023 /PRNewswire/ -- PTC Therapeutics, Inc.
Apr 13, 2023 PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
SOUTH PLAINFIELD, N.J. , April 13, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, April 27 ,
Mar 28, 2023 PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , March 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023 , the company approved non-statutory stock options to purchase an aggregate of 58,465 shares of its common stock and 29,710 restricted stock units ("RSUs"), each
Mar 24, 2023 Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
- Chief Operating Officer Matthew Klein , M.D., M.S., F.A.C.S. to become  Chief Executive Officer and join the Board of Directors –  - Conference call to be held today, Fri., March 24 th at 8:30 am ET - SOUTH PLAINFIELD, N.J. , March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ).
Feb 21, 2023 PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– 2022 total revenue of $699 million , representing 30% year-over-year growth,  or $740 million and 37% growth at CER* – – Guidance for full-year 2023 total revenue of $940 million to $1 billion reaffirmed – – Four important study readouts expected in first half of 2023, three of them
Feb 21, 2023 PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb. 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:     Raymond James 44 th Annual Institutional Investor Conference Monday, March 6 , at 8:05 a.m.
Feb 07, 2023 PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2022 financial results and provide an update on the company's business and outlook on Tuesday,
Feb 03, 2023 PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J. , Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of
Feb 02, 2023 PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , Feb. 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference:     SVB Securities Global Biopharma Conference Tuesday, Feb. 14 at 9:20 a.m.
Jan 19, 2023 NICE Recommends Reimbursement for Translarna™
- Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Jan. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final